This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

Clinical efficacy & safetyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-2 summaryPALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)SafetySafety overviewPooled ARsPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresIBRANCE long-term safetyGI and liver toxicitiesEffect of IBRANCE on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyRW evidenceValue of RWEWhat is real-world evidence?What is the value of RWE?P-REALITY and P-REALITY XP-REALITY OverviewP-REALITY OS and rwPFSP-REALITY X OverviewP-REALITY X OS and rwPFSIRISIRIS OverviewIRIS PFS and OSPOLARIS POLARIS OverviewPOLARIS Patient-Reported OutcomesMADELINEMADELINE OverviewMADELINE Patient CharacteristicsMADELINE Patient-Reported OutcomesPalomAGEPalomAGE OverviewRWE in Older Patients with mBCPatient-reported outcomesPALOMA-2: FACT-B scoresPALOMA-3: EORTC QLQ-C30 scoresPALOMA-3: Time to deterioration in pain symptomsDosingRecommended dosing scheduleRecommended dose modifications for AEsMonitoringOne scheduled monitoring provision ResourcesMaterials
Confidence built on strength

IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:

  • in combination with an aromatase inhibitor;
  • in combination with fulvestrant in women who have received prior endocrine therapy

In pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1

Please see Full Prescribing lnformation and Patient lnformation

 RCT PALOMA 2 & PALOMA 3

PALOMA was the first clinical trial programme to explore how a CDK4/6 inhibitor could benefit women with HR+/HER2- mBC10

 Explore PALOMA 2 & PALOMA 3 RWE complements RCTs

With RCT data,1-6 IBRANCE RWE7-9 can help improve understanding of outcomes in patients with HR+/HER2- mBC and help you to better support your patients

 Learn more about RWE Healthcare Professional Resources

Please note the materials are intended for healthcare professionals to effectively support patient care.

 Click here for HCP Resources Provide your patients with proven strength

A broad range of women with HR+/HER2- mBC may benefit from IBRANCE combination therapy.1-9 IBRANCE is the first CDK4/6 inhibitor supported by data from clinical trials1-4 and real-world evidence.5-7

 Find out more TitleAlmost 460,000 patients have been prescribed IBRANCE since FDA approval in 2015, as of January 202211​​​​​​​ Resources Find out more
CDK = cyclin-dependent kinase; FDA = Food and Drug Administration; HR+/HER2- = hormone receptor-positive, human epidermal growth factor 2-negative; mBC = metastatic breast cancer;  RCT = randomised controlled trial; RWE = real-world evidence.References:IBRANCE Summary of Product Characteristics.
Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729.
Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.
Cristofanilli M, et al. ASCO 2021; Oral presentation 1000.
Rugo HS, et al. Oncologist. 2021;26(8):e1339-e1346.
DeMichele A, et al. Breast Cancer Res. 2021;23:37.
Taylor-Stokes G, et al. Breast. 2019;43:22-27.
Waller J, et al. J Glob Oncol. 2019;5:JGO1800239.
McCain J. P T. 2015;40(8):511-520.
IBRANCE data on file. Patients prescribed IBRANCE worldwide.

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0587. January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.